Compare NTCT & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | AVDL |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1999 | 1996 |
| Metric | NTCT | AVDL |
|---|---|---|
| Price | $27.77 | $21.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $32.00 | $18.38 |
| AVG Volume (30 Days) | 492.9K | ★ 2.8M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $862,770,000.00 | $248,517,000.00 |
| Revenue This Year | $5.90 | $65.47 |
| Revenue Next Year | $2.62 | $30.88 |
| P/E Ratio | $22.19 | ★ N/A |
| Revenue Growth | 9.60 | ★ 79.88 |
| 52 Week Low | $18.12 | $6.38 |
| 52 Week High | $30.67 | $23.57 |
| Indicator | NTCT | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 59.42 |
| Support Level | $27.44 | $21.34 |
| Resistance Level | $28.20 | $21.55 |
| Average True Range (ATR) | 0.53 | 0.24 |
| MACD | 0.10 | -0.24 |
| Stochastic Oscillator | 76.37 | 13.46 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.